Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

11 questions · 11 findings · 2 reviews · Dementia and Cognitive Improvement

No studies found 4 · 36.4%GRADE not reported 0 · 0%Very low 1 · 9.1%Low 6 · 54.5%Moderate 0 · 0%High 0 · 0%

Rivastigmine vs placebo

Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments

It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).

1 finding from 1 review

Rivastigmine vs placebo

Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments

Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).

1 finding from 1 review